Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

被引：1
|
作者：
Venugopal, Sangeetha [1 ]
Kadia, Tapan M. [1 ]
Ravandi, Farhad [1 ]
DiNardo, Courtney D. [1 ]
Daver, Naval [1 ]
Borthakur, Gautam [1 ]
Konopleva, Marina [1 ]
Garcia-Manero, Guillermo [1 ]
Montalban-Bravo, Guillermo [1 ]
Maiti, Abhishek [1 ]
Yilmaz, Musa [1 ]
Issa, Ghayas C. [1 ]
Chien, Kelly S. [1 ]
Pierce, Sherry A. [1 ]
Kantarjian, Hagop [1 ]
Short, Nicholas J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153960
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
794
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
    Nicholas J. Short
    Sangeetha Venugopal
    Wei Qiao
    Tapan M. Kadia
    Farhad Ravandi
    Walid Macaron
    Courtney D. Dinardo
    Naval Daver
    Marina Konopleva
    Gautam Borthakur
    Elizabeth J. Shpall
    Uday Popat
    Richard E. Champlin
    Rohtesh Mehta
    Gheath Al-Atrash
    Betul Oran
    Elias Jabbour
    Guillermo Garcia-Manero
    Ghayas C. Issa
    Guillermo Montalban-Bravo
    Musa Yilmaz
    Abhishek Maiti
    Hagop Kantarjian
    Journal of Hematology & Oncology, 15
  • [2] Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
    Short, Nicholas J.
    Venugopal, Sangeetha
    Qiao, Wei
    Kadia, Tapan M.
    Ravandi, Farhad
    Macaron, Walid
    Dinardo, Courtney D.
    Daver, Naval
    Konopleva, Marina
    Borthakur, Gautam
    Shpall, Elizabeth J.
    Popat, Uday
    Champlin, Richard E.
    Mehta, Rohtesh
    Al-Atrash, Gheath
    Oran, Betul
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Maiti, Abhishek
    Kantarjian, Hagop
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [3] Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies
    Arana, Cecilia Y.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Wierda, William G.
    Borthakur, Gautam
    Quintas-Cardama, Alfonso
    Konopleva, Marina
    Faderl, Stefan
    Pierce, Sherry A.
    Andreeff, Michael
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [4] The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent
    Ozga, Michael
    Huang, Ying
    Blachly, James S.
    Grieselhuber, Nicole R.
    Wall, Sarah
    Larkin, Karilyn
    Haque, Tamanna
    Walker, Alison R.
    Bhatnagar, Bhavana
    Behbehani, Gregory
    Vasu, Sumithira
    Maakaron, Joseph E.
    Lustberg, Mark
    Mims, Alice S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01): : E76 - E83
  • [5] Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Winer, Eric S.
    Luskin, Marlise R.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, Coleman
    Copson, Kevin
    Charles, Anne
    Neuberg, Donna S.
    Issa, Nicolas C.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Garcia, Jacqueline S.
    BLOOD, 2021, 138
  • [6] Secondary MDS/AML in patients treated for myeloma.
    Saso, R
    Kulkarni, S
    Powles, R
    Treleaven, J
    Wilson, K
    Swansbury, J
    Sastry, P
    Ramiah, V
    Horton, C
    Mehta, J
    Catovsky, D
    BLOOD, 1998, 92 (10) : 455A - 455A
  • [7] Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach
    Boddu, Prajwal Chaitanya
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Ravandi, Farhad
    Jabbour, Elias J.
    Takahashi, Koichi
    Bhalla, Kapil N.
    Konopleva, Marina
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jain, Nitin
    Pierce, Sherry
    Wierda, William G.
    Cortes, Jorge E.
    Kadia, Tapan M.
    BLOOD, 2016, 128 (22)
  • [8] Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Harris, Courtney E.
    Winer, Eric S.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, R. Coleman
    Copson, Kevin M.
    Charles, Anne
    Marty, Francisco
    Neuberg, Donna
    DeAngelo, Daniel J.
    Stone, Richard M.
    Luskin, Marlise R.
    Issa, Nicolas C.
    Garcia, Jacqueline S.
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1934 - 1941
  • [9] Survival Outcomes Associated with Molecular and Cytogenetic Alterations in AML Patients Treated with Hypomethylating Agent and Venetoclax
    Boisclair, Stephanie
    Naing, Phyu Thin
    Zhou, Edward
    Thakur, Richa
    Goldberg, Bradley
    Jou, Erin
    Chitty, David W.
    Kolitz, Jonathan E.
    BLOOD, 2023, 142
  • [10] Influence of cytogenetics on prognosis of secondary AML patients ≤60 years with documented MDS prior to diagnosis of AML.
    Schaich, M
    Schäkel, U
    Mohr, B
    Pascheberg, U
    Soucek, S
    Bornhäuser, M
    Gramatzki, M
    Ehninger, G
    BLOOD, 2000, 96 (11) : 711A - 711A
12345